David A. Siegel Amylyx Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 143,000 shares of AMLX stock, worth $1.81 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
143,000
Previous 470,000
69.57%
Holding current value
$1.81 Million
Previous $3.01 Million
35.49%
% of portfolio
0.0%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding AMLX
# of Institutions
184Shares Held
94.1MCall Options Held
421KPut Options Held
174K-
Perceptive Advisors LLC New York, NY8.95MShares$114 Million0.27% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.82MShares$86.5 Million0.16% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.24MShares$79.2 Million9.51% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.27MShares$66.9 Million0.0% of portfolio
-
Saturn V Capital Management LLC Austin, TX4.6MShares$58.4 Million13.72% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $743M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...